NEW YORK – Resolve Biosciences, a startup developing a spatial multiomics analysis platform, emerged from stealth on Thursday and announced it has raised a $24 million Series A financing round.
PS Capital Management and Mastermind Advisory Services led the round, joined by Alafi Capital, John Shoffner, and High Tech Gründerfonds.
In a statement, Resolve said it would use the funding to "accelerate product development and drive industry adoption of its Molecular Cartography technology." The firm said its platform would deliver high-resolution spatial analysis of transcriptomic activity of hundreds of genes at a time, while preserving sample tissue.
"Molecular Cartography creates a new dimension of spatial analysis, which will soon expand the frontiers of modern molecular biology," Resolve Cofounder and Chairman Peer Schatz said in a statement. "Our innovative solution enables valuable scientific insights that far exceed the reach of legacy spatial biology technologies." Schatz was CEO of Qiagen from 2004 to 2019.
Resolve, based in Monheim am Rhein, Germany, said it has been developing its technology since 2016.
"Resolve Biosciences' pioneering Molecular Cartography platform powers novel insights by enabling scientists to gain the highest-resolution view of subcellular gene expression activity," CEO Jason Gammack said in a statement. "Together with our talented team of scientists and investors, we are poised to lead the next generation of single-cell analysis and support scientists around the world as they apply the latest advances of our Molecular Cartography technology platform to solve the most complex biological questions."